BLA 125019 · Spectrum Pharms
Zevalin
Ibritumomab Tiuxetan · Injection
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 11, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Feb 19, 2002
Approved uses
5
Original approval plus efficacy supplements
Registered trials
99
13 Phase 3, 0 recruiting
FAERS reports
1,523
1,418 serious, 551 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS, and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab infusion, an essential component of the Zevalin therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most (80%) fatalities occurred with the first rituximab infusion [ see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 ) ] . Discontinue rituximab and Y-90 Zevalin infusions in patients who develop severe infusion reactions. Prolonged and Severe Cytopenias: Y-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Do not administer Y-90 Zevalin to patients with ≥ 25% lymphoma marrow involvement and/or...
What it is approved for
From the label in effect Apr 25, 2023.
Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) ( 1.1 ). previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy ( 1.2 ). 1.1 Relapsed or Refractory, Low-grade or Follicular NHL Zevalin is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). 1.2 Previously Untreated Follicular NHL Zevalin is indicated for the treatment of previously untreated follicular NHL in adult patients who achieve a partial or complete response to first-line chemotherapy.
Mechanism: Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35). The apparent affinity (K D ) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin’s lymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding. The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90 induces cellular damage by the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 18, 2011 Supplement 194 · Efficacy LabelLetter
- Sep 3, 2009 Supplement 156 · Efficacy · priority review OrphanLabelLetter
- Jul 27, 2005 Supplement 88 · Efficacy OrphanLabelLetter
- Oct 22, 2004 Supplement 58 · Efficacy OrphanLabelLetter
- Feb 19, 2002 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewLetter
1 products under this application
- ZEVALIN · IBRITUMOMAB TIUXETAN 3.2MG/2ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ibritumomab Tiuxetan" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular LymphomaPivotal-lookingCompleted
Fondazione Italiana Linfomi - ETSAcademic, hospital or other
NCT02063685 · 807 participants · Start Jul 2012 · Primary completion Dec 2021
Drug: R-CHOP or R-bendamustine; Observation and 3 more · For: Follicular Non-Hodgkin's Lymphoma
Sites: Meldola, Italy; Civitanova Marche, Italy; Rozzano, Italy · 48 sites in all
- Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line ChemotherapyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00185393 · 414 participants · Start Aug 2001
Drug: Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128) · For: Lymphoma, Non-Hodgkin
Sites: Antwerp, Belgium; Bruges, Belgium; Brussels, Belgium · 95 sites in all
- Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's LymphomaPivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT00057343 · 400 participants · Start Mar 2003
Drug: Zevalin (ibritumomab tiuxetan); Rituxan (rituximab) · For: Non-Hodgkin's Lymphoma
Sites: Huntsville, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 67 sites in all
Oslo University HospitalAcademic, hospital or other
NCT00514475 · 160 participants · Start Nov 2005 · Primary completion Jun 2009
Drug: 90Y-ibritumomab tiuxetan (Zevalin) · For: Mantle Cell Lymphoma
Sites: Oslo, Norway
- A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)Pivotal-lookingCompleted
Fondazione Italiana Linfomi - ETSAcademic, hospital or other
NCT01827605 · 159 participants · Start Jan 2012 · Primary completion Oct 2019
Drug: BEAM · For: Relapsed Follicular Lymphoma
Sites: Alessandria, Italy; Ancona, Italy; Bari, Italy · 38 sites in all
- S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell LymphomaCompleted
SWOG Cancer Research NetworkResearch network
NCT01359592 · 159 participants · Start Sep 2011 · Primary completion Jun 3, 2020
Drug: rituximab; cyclophosphamide and 3 more · For: Lymphoma
Sites: Anchorage, Alaska; Tucson, Arizona; Aurora, Colorado · 240 sites in all
- ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)Pivotal-lookingCompleted
PETHEMA FoundationAcademic, hospital or other
NCT00662948 · 149 participants · Start Dec 2008 · Primary completion Oct 2014
Drug: Rituximab; Ibritumomab tiuxetan · For: Lymphoma
Sites: A Coruña, Spain; Alcorcón, Spain; Badalona, Spain · 21 sites in all
City of Hope Medical CenterAcademic, hospital or other
NCT00695409 · 122 participants · Start Mar 18, 2008 · Primary completion Mar 27, 2017
Drug: rituximab; carmustine and 3 more · For: Lymphoma
Sites: Duarte, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- thrombocytopenia174
- sepsis172
- neutropenia141
- meningitis tuberculous128
- myelodysplastic syndrome98
- febrile neutropenia94
- off label use93
- progressive multifocal leukoencephalopathy90
- disease progression85
- anaemia84
- platelet count decreased84
- white blood cell count decreased83
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 146 |
| 2005 | 56 |
| 2006 | 85 |
| 2007 | 69 |
| 2008 | 78 |
| 2009 | 164 |
| 2010 | 101 |
| 2011 | 75 |
| 2012 | 63 |
| 2013 | 47 |
| 2014 | 35 |
| 2015 | 76 |
| 2016 | 46 |
| 2017 | 64 |
| 2018 | 96 |
| 2019 | 49 |
| 2020 | 64 |
| 2021 | 127 |
| 2022 | 21 |
| 2023 | 30 |
| 2024 | 14 |
| 2025 | 15 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
Luminari S, Manni M, Galimberti S, et al. · J Clin Oncol 2022 · Clinical Trial, Phase III, Multicenter Study
- Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.
Yasuda H, Yasuda M, Komatsu N · Cancer Sci 2021 · Systematic Review
- Extravasation of Therapeutic Radiopharmaceuticals: A Systematic Review and Management Proposal.
Gebruers J, Terwinghe C, Graven LH, et al. · J Nucl Med 2025 · Systematic Review
- Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.
Miura K, Tsujimura H, Masaki Y, et al. · Hematol Oncol 2021 · Clinical Trial, Phase II, Multicenter Study
- Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.
Emmanouilides C, Witzig TE, Wiseman GA, et al. · Cancer Biother Radiopharm 2007 · Meta-Analysis
- Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.
Auger-Quittet S, Duny Y, Daures JP, et al. · Cancer Med 2014 · Meta-Analysis, Review
Sponsor: Spectrum Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.